MRK vs PLTR: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Palantir Technologies Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
VS
Palantir Technologies Inc. · Technology
$133.79
-41.7% upside to fair value
Grade C
High Quality
QuantHub Verdict
MRK has more upside to fair value
(+3.3%).
MRK trades at a lower forward P/E
(22.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
PLTR |
| Current Price |
$114.27 |
$133.79 |
| Fair Value Estimate |
$118.00 |
$78.04 |
| Upside to Fair Value |
+3.3%
|
-41.7%
|
| Market Cap |
$282.2B |
$306.6B |
| Forward P/E |
22.4x
|
140.4x
|
| EV / EBITDA |
13.5x
|
151.4x
|
| Price / Sales |
4.3x
|
58.7x
|
| Price / FCF |
20.2x
|
114.0x
|
| Revenue Growth YoY |
+5.0%
|
+84.7%
|
| Gross Margin |
81.9%
|
84.1%
|
| Operating Margin |
27.5%
|
38.1%
|
| Return on Equity |
5.6%
|
32.2%
|
| Dividend Yield |
2.91% |
0% |
| FCF Yield |
4.95%
|
0.88%
|
| Analyst Consensus |
Overweight
|
Buy
|
Investment Thesis
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Palantir Technologies Inc. is a high-growth enterprise software company specializing in data analytics and intelligence platforms for government and commercial clients. The company benefits from a durable competitive moat through its established government contracts, proprietary platforms Gotham and Foundry, and expanding commercial footprint. Palantir's revenue grew 84.7% year-over-year in the m…
Accumulation Zones
| Metric |
MRK |
PLTR |
| Zone Low |
$88.50 |
$58.53 |
| Zone High |
$100.30 |
$66.33 |
| In Buy Zone? |
No
|
No
|